Program
AP31969
A development code.
Its studies are mostly in Atrial Fibrillation · Arrhythmias, Cardiac, led by Acesion Pharma.
Furthest: phase 2, since Nov 25, 20253 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Acesion Pharma | 31 open or running | phase 2since Nov 25, 2025 | Sep 27, 2023 | May 2027phase 2 · NCT07267949 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 27, 2023First study: phase 1 study in Arrhythmias, CardiacFirst studyNCT06066099 · 92 enrolled · Netherlands
- Nov 25, 2025Phase 2 study in Atrial FibrillationPhase 2 reachedNCT07267949 · 200 planned · Bulgaria, Denmark, Germany and more
- Feb 27, 2026Phase 1 study in Healthy ParticipantsNCT07449390 · 28 enrolled · United States
Ahead
- May 2027Primary completion: phase 2 study in Atrial FibrillationNCT07267949
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07449390Healthy Participants · United States | 1 | Completed | May 9, 2026 | 28 |
| NCT07267949Atrial Fibrillation · Bulgaria, Denmark, Germany and more | 2 | Recruiting | May 2027 | 200 |
| NCT06066099Arrhythmias, Cardiac · Netherlands | 1 | Completed | Mar 14, 2025 | 92 |
How it is read
Names in the registry
- “AP31969”, 3 entries
Codes read as this program: AP31969.
Conditions, from the studies’ own filings
- Atrial Fibrillation, 1 study
- Arrhythmias, Cardiac, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.